Zafgen Grabs $8.1M More in B Round

Xconomy Boston — 

Zafgen, a Cambridge, MA-based startup focused on new obesity treatments, has raised $8.1 million in a third closing of its $28 million Series B round, a company spokeswoman confirmed this afternoon. The funding was revealed today in this SEC filing. The company, which has now raised $30 million, received the fresh capital from previous backers Third Rock Ventures in Boston and Atlas Venture in Waltham, MA. Zafgen CEO Tom Hughes told Luke earlier this year that the firm isn’t exactly sure how its drugs work, after a study showed that its earlier hypothesis that its molecules cut off the blood supply to fat tissues turned out be wrong.